Dr. Hance Clarke on The Medical Cannabis Real-World Evidence Study & Catherine Iniss …
#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
# Clinical Summary The University Health Network is initiating a real-world evidence study to systematically evaluate medical cannabis efficacy for specific clinical conditions, addressing a significant gap in the clinical literature where regulatory approval has outpaced rigorous evidence generation. Real-world evidence studies track patient outcomes in actual clinical practice settings rather than controlled trials, providing practical data on effectiveness, safety, and optimal dosing across diverse patient populations and comorbidities. This research approach is particularly valuable for cannabis medicine, where heterogeneous patient populations, variable product formulations, and inconsistent dosing regimens have complicated evidence-based practice. By generating robust clinical data on conditions where patients are already using cannabis therapeutically, researchers can help clinicians distinguish between anecdotal benefit and evidence-supported indications, thereby improving prescribing confidence and patient outcomes. For clinicians, this study offers the opportunity to contribute clinical observations to a structured database while gaining access to emerging evidence on efficacy and safety profiles. Physicians should anticipate that real-world evidence from this study may refine clinical guidance on cannabis dosing, strain selection, and appropriate patient populations, ultimately supporting more informed clinical decision-making.
“The real-world evidence we’re gathering through studies like this is valuable because it captures how cannabis actually performs in clinical practice rather than under tightly controlled conditions, but we need to be clear that observational data tells us what’s happening, not necessarily why it’s happening or whether we’re seeing true efficacy or confounding effects. What gets me excited is when we can eventually link these real-world patterns to rigorous randomized trials, because that’s where we can actually inform clinical decision-making with confidence.”
💊 While real-world evidence studies on medical cannabis can provide valuable insights into clinical outcomes outside rigorous trial conditions, healthcare providers should interpret such data with appropriate caution, as observational designs are susceptible to selection bias, placebo effects, and confounding by indication that are difficult to fully control. The emerging evidence from academic health networks like the University Health Network helps address the substantial knowledge gap regarding cannabis efficacy for specific conditions, yet heterogeneity in cannabis products, dosing, administration routes, and patient populations across real-world studies limits generalizability to individual clinical decisions. Clinicians should remain aware that regulatory frameworks and available evidence differ significantly across jurisdictions, and that many patients are already using cannabis regardless of guideline status, creating a clinical reality where informed shared decision-making becomes essential. Given these complexities, the most practical approach is to systematically document patient-reported outcomes when cannabis is used, maintain awareness of emerging trial data, and counsel patients
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
